Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Hikma Pharmaceuticals Plc (PK) HKMPF

Alternate Symbol(s):  HKMPY

Healthcare Drug Manufacturers - Specialty & Generic
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to... see more

Recent & Breaking News (PINL:HKMPF)

Hikma launches TYZAVAN(TM) (vancomycin injection, USP) in the US

PR Newswire December 8, 2025

Hikma receives FDA approval for TYZAVAN(TM) (Vancomycin Injection, USP) in the US

PR Newswire July 2, 2025

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

PR Newswire June 28, 2025

Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

PR Newswire May 27, 2025

Hikma acquires Novugen's FDA-approved ANDA for trametinib

PR Newswire April 17, 2025

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

GlobeNewswire March 20, 2025

Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg

PR Newswire January 14, 2025

Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day

PR Newswire August 20, 2024

KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months

PR Newswire August 15, 2024

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

PR Newswire February 21, 2024

Hikma announces US launch of COMBOGESIC® IV

PR Newswire February 5, 2024

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Business Wire January 8, 2024

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

PR Newswire October 3, 2023

Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox(TM) Platform Cancer Treatment in the Middle East and North Africa

PR Newswire August 10, 2023

Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases

PR Newswire July 26, 2023

Hikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USP

PR Newswire June 15, 2023

Hikma expands impact in Canada with launches of new sterile injectable medicines

PR Newswire March 9, 2023

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

GlobeNewswire December 26, 2022

Hikma launches RYALTRIS(TM) seasonal allergic rhinitis nasal spray in the US

PR Newswire August 30, 2022

Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

PR Newswire April 29, 2022

Podcasts